CS
MRNA icon

Credit Suisse’s Moderna MRNA Stock Holding History

Credit Suisse’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$57.5M Sell
539,488
-312,544
-37% -$31.5M 0.06% 334
2023
Q4 		$84.7M Sell
852,032
-82,397
-9% -$6.93M 0.08% 237
2023
Q3 		$96.5M Buy
934,429
+150,932
+19% +$16.8M 0.1% 197
2023
Q2 		$95.2M Buy
783,497
+78,700
+11% +$10.5M 0.09% 216
2023
Q1 		$108M Buy
704,797
+121,742
+21% +$20.1M 0.11% 190
2022
Q4 		$105M Sell
583,055
-175,825
-23% -$28.7M 0.11% 192
2022
Q3 		$89.7M Sell
758,880
-164,227
-18% -$24.9M 0.1% 211
2022
Q2 		$132M Buy
923,107
+199,346
+28% +$28.5M 0.14% 153
2022
Q1 		$125M Sell
723,761
-151,341
-17% -$25.5M 0.11% 200
2021
Q4 		$222M Sell
875,102
-234,979
-21% -$68.7M 0.12% 158
2021
Q3 		$427M Sell
1,110,081
-100,211
-8% -$37M 0.24% 65
2021
Q2 		$284M Sell
1,210,292
-117,069
-9% -$20.9M 0.15% 123
2021
Q1 		$174M Sell
1,327,361
-398,619
-23% -$57.8M 0.09% 241
2020
Q4 		$180M Buy
1,725,980
+385,031
+29% +$39M 0.09% 234
2020
Q3 		$94.9M Buy
1,340,949
+80,382
+6% +$5.6M 0.06% 363
2020
Q2 		$80.9M Sell
1,260,567
-417,781
-25% -$22.9M 0.06% 346
2020
Q1 		$50.3M Sell
1,678,348
-1,205,563
-42% -$27.7M 0.04% 434
2019
Q4 		$56.4M Buy
2,883,911
+288,707
+11% +$5.12M 0.04% 483
2019
Q3 		$41.3M Buy
2,595,204
+491,879
+23% +$7.27M 0.03% 543
2019
Q2 		$30.8M Buy
2,103,325
+1,051,116
+100% +$22.6M 0.03% 691
2019
Q1 		$21.4M Buy
1,052,209
+452,209
+75% +$8.39M 0.02% 829
2018
Q4 		$9.16M Buy
+600,000
New +$9.86M 0.01% 1198

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Credit Suisse's MRNA Position: Q1 2024 in Review

Credit Suisse reduced its Moderna (MRNA) stake by 37% in Q1 2024, selling an estimated $31.5M and leaving 539,488 shares worth $57.5M. The position accounts for 0.06% of the portfolio, ranked #334.

Credit Suisse first reported a position in MRNA in Q4 2018 and has held it in 22 quarters since. The position peaked at $427M in Q3 2021. 903 funds tracked by Wall St. Rank hold MRNA as of Q1 2024.

  • Credit Suisse held 539,488 shares of Moderna worth $57.5M as of Q1 2024.
  • Credit Suisse sold 312,544 Moderna shares in Q1 2024, an estimated $31.5M.
  • Moderna made up 0.06% of Credit Suisse's portfolio in Q1 2024, its #334 holding.
  • Credit Suisse first reported a position in Moderna in Q4 2018 and has held it in 22 quarters since.
  • Credit Suisse's Moderna position peaked at $427M in Q3 2021.
  • 903 funds tracked by Wall St. Rank held Moderna as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.